↓ Skip to main content

Dove Medical Press

Article Metrics

New developments in atherosclerosis: clinical potential of PCSK9 inhibition.

Overview of attention for article published in Vascular Health and Risk Management, January 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
7 tweeters
googleplus
1 Google+ user

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
49 Mendeley
citeulike
1 CiteULike
Title
New developments in atherosclerosis: clinical potential of PCSK9 inhibition.
Published in
Vascular Health and Risk Management, January 2015
DOI 10.2147/vhrm.s74692
Pubmed ID
Authors

Hagai Tavori, Ilaria Giunzioni

Abstract

Pro-protein convertase subtilisin/kexin type 9 (PCSK9) is a secreted 692-amino acid protein that binds surface low-density lipoprotein (LDL) receptor (LDLR) and targets it toward lysosomal degradation. As a consequence, the number of LDLRs at the cell surface is decreased, and LDL-cholesterol (LDL-C) clearance is reduced, a phenomenon that is magnified by gain-of-function mutations of PCSK9. In contrast, loss-of-function mutations of PCSK9 result in increased surface LDLR and improved LDL-C clearance. This provides the rationale for targeting PCSK9 in hypercholesterolemic subjects as a means to lower LDL-C levels. Monoclonal antibodies (mAbs) against PCSK9 that block its interaction with the LDLR have been developed in the past decade. Two companies have recently received the approval for their anti-PCSK9 mAbs by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Regeneron/Sanofi, with alirocumab (commercial name - PRALUENT(®)) and, Amgen with evolocumab (commercial name - Repatha™). The introduction of anti-PCSK9 mAbs will provide an alternative therapeutic strategy to address many of the unmet needs of current lipid-lowering therapies, such as inability to achieve goal LDL-C level, or intolerance and aversion to statins. This review will focus on the kinetics of PCSK9, pharmacokinetics and pharmacodynamics of anti-PCSK9 mAbs, and recent data linking PCSK9 and anti-PCSK9 mAbs to cardiovascular events. Moreover, it will highlight the unanswered questions that still need to be addressed in order to understand the physiologic function, kinetics, and dynamics of PCSK9.

Twitter Demographics

The data shown below were collected from the profiles of 7 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 49 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 1 2%
Germany 1 2%
Unknown 47 96%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 9 18%
Student > Master 8 16%
Student > Postgraduate 6 12%
Student > Ph. D. Student 6 12%
Researcher 5 10%
Other 11 22%
Unknown 4 8%
Readers by discipline Count As %
Medicine and Dentistry 14 29%
Pharmacology, Toxicology and Pharmaceutical Science 8 16%
Biochemistry, Genetics and Molecular Biology 8 16%
Agricultural and Biological Sciences 7 14%
Immunology and Microbiology 1 2%
Other 4 8%
Unknown 7 14%

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 September 2015.
All research outputs
#4,642,583
of 18,734,754 outputs
Outputs from Vascular Health and Risk Management
#151
of 669 outputs
Outputs of similar age
#59,506
of 247,501 outputs
Outputs of similar age from Vascular Health and Risk Management
#7
of 24 outputs
Altmetric has tracked 18,734,754 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 669 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 247,501 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.